285 related articles for article (PubMed ID: 33230571)
1. Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes.
Krajewski W; Moschini M; Chorbińska J; Nowak Ł; Poletajew S; Tukiendorf A; Afferi L; Teoh JY; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Cianflone F; Mari A; Di Trapani E; Hendricksen K; Alvarez-Maestro M; Rodríguez-Serrano A; Simone G; Zamboni S; Simeone C; Marconi MC; Mastroianni R; Ploussard G; Laukhtina E; Tully K; Kołodziej A; Krajewska J; Piszczek R; Xylinas E; Zdrojowy R;
World J Urol; 2021 Jul; 39(7):2545-2552. PubMed ID: 33230571
[TBL] [Abstract][Full Text] [Related]
2. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY;
Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948
[TBL] [Abstract][Full Text] [Related]
3. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
[TBL] [Abstract][Full Text] [Related]
4. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
6. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
[TBL] [Abstract][Full Text] [Related]
7. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
8. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
[TBL] [Abstract][Full Text] [Related]
9. Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit.
Krajewski W; Moschini M; Nowak Ł; Poletajew S; Tukiendorf A; Afferi L; Teoh J; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Gozzo A; Mari A; Di Trapani E; Hendricksen K; Alvarez-Maestro M; Serrano AR; Simone G; Zamboni S; Simeone C; Marconi MC; Mastroianni R; Ploussard G; Rajwa P; Laukhtina E; Zdrojowy-Wełna A; Kołodziej A; Paradysz A; Tully K; Krajewska J; Piszczek R; Xylinas E; Zdrojowy R
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33076249
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
[TBL] [Abstract][Full Text] [Related]
11. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
12. Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.
Ferro M; Katalin MO; Buonerba C; Marian R; Cantiello F; Musi G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; Del Giudice F; Perdonà S; Del Prete P; Mirone V; Borghesi M; Porreca A; Artibani W; Bove P; Lima E; Autorino R; Crisan N; Abu Farhan AR; Battaglia M; Ditonno P; Serretta V; Russo GI; Terracciano D; di Lorenzo G; Damiano R; Sonpavde G; Vartolomei MD; de Cobelli O; Lucarelli G
Urol Oncol; 2020 May; 38(5):459-464. PubMed ID: 32173242
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the oncological outcomes of three different bacillus Calmette-Guérin strains in patients with high-grade T1 non-muscle-invasive bladder cancer.
Nowak Ł; Krajewski W; Moschini M; Chorbińska J; Poletajew S; Tukiendorf A; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Orlando R; Di Trapani E; Alvarez-Maestro M; Simone G; Zamboni S; Simeone C; Marconi MC; Mastroianni R; Piszczek R; Xylinas E; Zdrojowy R;
Arab J Urol; 2021 Jan; 19(1):78-85. PubMed ID: 33763252
[TBL] [Abstract][Full Text] [Related]
14. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
[TBL] [Abstract][Full Text] [Related]
16. Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study.
Lee S; Lim B; You D; Hong B; Hong JH; Kim CS; Ahn H; Jeong IG
Urol Oncol; 2020 Nov; 38(11):851.e11-851.e17. PubMed ID: 32800440
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
18. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
Huang B; Huang G; Li W; Chen L; Mao X; Chen J
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
[TBL] [Abstract][Full Text] [Related]
19. The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
Krajewski W; Zdrojowy R; Dembowski J; Poletajew S; Wróbel M; Łuczak M; Tukiendorf A; Kolodziej A
Urol Int; 2019; 102(1):60-68. PubMed ID: 30269132
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guérin immunotherapy.
Piszczek R; Krajewski W; Subiela JD; Del Giudice F; Nowak Ł; Chorbińska J; Moschini M; Masson-Lecomte A; Bebane S; Cimadamore A; Grobet-Jeandin E; Rouprêt M; D'Andrea D; Mastroianni R; Gutierrez Hidalgo B; Gomez Rivas J; Mori K; Soria F; Laukhtina E; Mari A; Albisinni S; Gallioli A; Mertens LS; Pichler R; Marcq G; Łaszkiewicz J; Hałoń A; Carrion DM; Akand M; Pradere B; Shariat SF; Palou J; Babjuk M; Burgos Revilla J; Małkiewicz B; Szydełko T;
Minerva Urol Nephrol; 2023 Oct; 75(5):591-599. PubMed ID: 37728495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
